A multicentre single arm phase 2 trial of neoadjuvant pyrotinib and letrozole plus dalpiciclib for triple-positive breast cancer

Current therapies for HER2-positive breast cancer have limited efficacy in patients with triple-positive breast cancer (TPBC). We conduct a multi-center single-arm phase 2 trial to test the efficacy and safety of an oral neoadjuvant therapy with pyrotinib, letrozole and dalpiciclib (a CDK4/6 inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: Niu, Nan, Qiu, Fang, Xu, Qianshi, He, Guijin, Gu, Xi, Guo, Wenbin, Zhang, Dianlong, Li, Zhigao, Zhao, Yi, Li, Yong, Li, Ke, Zhang, Hao, Zhang, Peili, Huang, Yuanxi, Zhang, Gangling, Han, Hongbin, Cai, Zhengang, Li, Pengfei, Xu, Hong, Chen, Guanglei, Xue, Jinqi, Jiang, Xiaofan, Jahromi, Alireza Hamidian, Li, Jinshi, Zhao, Yu, de Faria Castro Fleury, Eduardo, Huo, Shiwen, Li, Huajun, Jerusalem, Guy, Tripodi, Domenico, Liu, Tong, Zheng, Xinyu, Liu, Caigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672048/
https://www.ncbi.nlm.nih.gov/pubmed/36396665
http://dx.doi.org/10.1038/s41467-022-34838-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9672048/
https://www.ncbi.nlm.nih.gov/pubmed/36396665
http://dx.doi.org/10.1038/s41467-022-34838-w

Ejemplares similares